New Partnership Aims to Expand Access to AI-Driven Cancer Genomic Testing
The collaboration combines AI-based analysis tools with a next-generation sequencing system to support labs performing tumor and liquid biopsy testing.
Read MorePosted by CLP Edit Staff | Dec 5, 2025 | Analytical Software Systems, Cancer, Molecular Diagnostics |
The collaboration combines AI-based analysis tools with a next-generation sequencing system to support labs performing tumor and liquid biopsy testing.
Read MorePosted by CLP Edit Staff | Dec 4, 2025 | Hematology & Serology |
The 2026 clinical lab fee schedule sets payment for CPT code 81195 at $1,853.22, up from $1,263.53 in 2025.
Read MorePosted by CLP Edit Staff | Dec 2, 2025 | Molecular Diagnostics |
UMBS-seq preserves DNA integrity while maintaining accuracy for cancer biomarker detection in liquid biopsies and tissue samples.
Read MorePosted by CLP Edit Staff | Dec 1, 2025 | Molecular Diagnostics |
The proposed order would shift these test systems to Class II with special controls, replacing the current PMA requirement for companion diagnostics and related oncology assays.
Read MorePosted by CLP Edit Staff | Nov 26, 2025 | Disease States |
The targeted assay detects X-linked dystonia-parkinsonism cases that standard sequencing methods have missed.
Read More